Evidence map›Paper›PMID 33632293›Full record

ArticleGenome medicine2021

Clinical-grade whole-genome sequencing and 3' transcriptome analysis of colorectal cancer patients.

Agata Stodolna, Miao He, Mahesh Vasipalli, Zoya Kingsbury, Jennifer Becq, Joanne D Stockton, Mark P Dilworth, Jonathan James, Toju Sillo, Daniel Blakeway and 4 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Agata StodolnaInstitute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Miao HeIllumina Cambridge, Granta Park, Cambridge, UK.
Mahesh VasipalliIllumina Cambridge, Granta Park, Cambridge, UK.
Zoya KingsburyIllumina Cambridge, Granta Park, Cambridge, UK.
Jennifer BecqIllumina Cambridge, Granta Park, Cambridge, UK.
Joanne D StocktonInstitute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Mark P DilworthInstitute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Jonathan JamesInstitute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Toju SilloInstitute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Daniel BlakewayInstitute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Stephen T WardUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Tariq IsmailUniversity Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Mark T RossIllumina Cambridge, Granta Park, Cambridge, UK.
Andrew D BeggsInstitute of Cancer and Genomic Medicine, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. A.Beggs@bham.ac.uk.ORCID 0000-0003-0784-2967
University of Birmingham · GBIllumina (United Kingdom) · GBUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

Cancer Research UK C31641/A23923Wellcome TrustWellcome Trust 102732/Z/13/Z
6 · The paper itself

Abstract

backgroundClinical-grade whole-genome sequencing (cWGS) has the potential to become the standard of care within the clinic because of its breadth of coverage and lack of bias towards certain regions of the genome. Colorectal cancer presents a difficult treatment paradigm, with over 40% of patients presenting at diagnosis with metastatic disease. We hypothesised that cWGS coupled with 3' transcriptome analysis would give new insights into colorectal cancer.

methodsPatients underwent PCR-free whole-genome sequencing and alignment and variant calling using a standardised pipeline to output SNVs, indels, SVs and CNAs. Additional insights into the mutational signatures and tumour biology were gained by the use of 3' RNA-seq.

resultsFifty-four patients were studied in total. Driver analysis identified the Wnt pathway gene APC as the only consistently mutated driver in colorectal cancer. Alterations in the PI3K/mTOR pathways were seen as previously observed in CRC. Multiple private CNAs, SVs and gene fusions were unique to individual tumours. Approximately 30% of patients had a tumour mutational burden of > 10 mutations/Mb of DNA, suggesting suitability for immunotherapy.

conclusionsClinical whole-genome sequencing offers a potential avenue for the identification of private genomic variation that may confer sensitivity to targeted agents and offer patients new options for targeted therapies.

Indexed as

Gene Expression ProfilingWhole Genome SequencingAdultAgedAged, 80 and overAntineoplastic AgentsCluster AnalysisColorectal NeoplasmsDatabases, GeneticDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticGerm-Line MutationHumansMaleMiddle AgedAntineoplastic AgentsChemoradiotherapyGenomicsPathological complete responseRectal cancer

Identifiers

PMID33632293
PMCPMC7908713
OpenAlexW3131530976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.